MAESTrO: CADTH calls for patient input on a submission from Gilead for sofosbuvir with velpatasvir

Posted by Michael Wonder on 23 Mar 2016

CADTH calls for patient input on a submission from Gilead for sofosbuvir with velpatasvir

23 March 2016 - CADTH has received notice of a pending submission from Gileda for sofosbuvir with velpatasvir for the treatment of patients with chronic hepatitis C virus infection.

For more details, go to: https://www.cadth.ca/sofosbuvir-velpatasvir

Posted by:

Michael Wonder

Posted in:

Health technology assessment , Combination product , Canada , Submission , Hepatitis C